25 XP   0   0   10

BB Biotech AG
Buy, Hold or Sell?

Let's analyse BB Biotech AG together

PenkeI guess you are interested in BB Biotech AG. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BB Biotech AG. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about BB Biotech AG

I send you an email if I find something interesting about BB Biotech AG.

Quick analysis of BB Biotech AG (30 sec.)










What can you expect buying and holding a share of BB Biotech AG? (30 sec.)

How much money do you get?

How much money do you get?
CHF9.30
When do you have the money?
1 year
How often do you get paid?
69.2%

What is your share worth?

Current worth
CHF42.52
Expected worth in 1 year
CHF36.01
How sure are you?
74.4%

+ What do you gain per year?

Total Gains per Share
CHF1.97
Return On Investment
4.8%

For what price can you sell your share?

Current Price per Share
CHF41.20
Expected price per share
CHF37.87 - CHF48.32
How sure are you?
50%

1. Valuation of BB Biotech AG (5 min.)




Live pricePrice per Share (EOD)

CHF41.20

Intrinsic Value Per Share

CHF-173.53 - CHF18.65

Total Value Per Share

CHF-131.00 - CHF61.18

2. Growth of BB Biotech AG (5 min.)




Is BB Biotech AG growing?

Current yearPrevious yearGrowGrow %
How rich?$2.5b$2.9b-$436.3m-17.5%

How much money is BB Biotech AG making?

Current yearPrevious yearGrowGrow %
Making money-$56.6m-$98m$41.4m73.2%
Net Profit Margin151.5%101.3%--

How much money comes from the company's main activities?

3. Financial Health of BB Biotech AG (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#27 / 1011

Most Revenue
#1011 / 1011

Most Profit
#903 / 1011

Most Efficient
#25 / 1011

What can you expect buying and holding a share of BB Biotech AG? (5 min.)

Welcome investor! BB Biotech AG's management wants to use your money to grow the business. In return you get a share of BB Biotech AG.

What can you expect buying and holding a share of BB Biotech AG?

First you should know what it really means to hold a share of BB Biotech AG. And how you can make/lose money.

Speculation

The Price per Share of BB Biotech AG is CHF41.20. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of BB Biotech AG.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in BB Biotech AG, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is CHF42.52. Based on the TTM, the Book Value Change Per Share is CHF-1.63 per quarter. Based on the YOY, the Book Value Change Per Share is CHF-2.54 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is CHF2.12 per quarter.
Based on historical numbers we can estimate the returns while holding a share of BB Biotech AG.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 CHF% of Price per ShareCHF% of Price per ShareCHF% of Price per ShareCHF% of Price per ShareCHF% of Price per Share
Usd Eps2.185.3%-1.03-2.5%-1.77-4.3%0.380.9%0.781.9%
Usd Book Value Change Per Share2.275.5%-1.79-4.3%-2.78-6.8%-0.52-1.3%0.120.3%
Usd Dividend Per Share0.000.0%2.335.6%3.678.9%3.348.1%2.425.9%
Usd Total Gains Per Share2.275.5%0.541.3%0.892.2%2.816.8%2.536.2%
Usd Price Per Share46.88-47.46-62.84-69.01-105.72-
Price to Earnings Ratio5.37--12.43--6.10--2.03-1.44-
Price-to-Total Gains Ratio20.64-12.01--29.56-1.69-148.01-
Price to Book Ratio1.01-1.05-1.18-1.15-1.71-
Price-to-Total Gains Ratio20.64-12.01--29.56-1.69-148.01-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share45.17992
Number of shares22
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share2.333.34
Usd Book Value Change Per Share-1.79-0.52
Usd Total Gains Per Share0.542.81
Gains per Quarter (22 shares)11.8761.86
Gains per Year (22 shares)47.49247.45
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1205-15737293-46237
2409-31484587-92484
3614-472131880-138731
4819-6291781174-184978
51023-7862251467-2301225
61228-9432721761-2761472
71433-11003192054-3221719
81637-12573662348-3681966
91842-14154132641-4142213
102047-15724602935-4602460

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%4.08.00.033.3%9.011.00.045.0%22.017.00.056.4%36.023.00.061.0%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%7.010.03.035.0%19.017.03.048.7%26.027.06.044.1%
Dividend per Share3.00.01.075.0%11.00.01.091.7%18.00.02.090.0%27.00.012.069.2%32.00.027.054.2%
Total Gains per Share3.01.00.075.0%8.04.00.066.7%14.06.00.070.0%29.010.00.074.4%38.020.01.064.4%

Fundamentals of BB Biotech AG

About BB Biotech AG

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.

Fundamental data was last updated by Penke on 2024-04-19 16:53:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of BB Biotech AG.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit BB Biotech AG earns for each CHF1 of revenue.

  • Above 10% is considered healthy but always compare BB Biotech AG to the Biotechnology industry mean.
  • A Net Profit Margin of 98.2% means that CHF0.98 for each CHF1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BB Biotech AG:

  • The MRQ is 98.2%. The company is making a huge profit. +2
  • The TTM is 151.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ98.2%TTM151.5%-53.4%
TTM151.5%YOY101.3%+50.2%
TTM151.5%5Y-9,227.9%+9,379.4%
5Y-9,227.9%10Y-4,683.0%-4,544.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ98.2%-196.1%+294.3%
TTM151.5%-211.9%+363.4%
YOY101.3%-277.7%+379.0%
5Y-9,227.9%-432.9%-8,795.0%
10Y-4,683.0%-599.3%-4,083.7%
1.1.2. Return on Assets

Shows how efficient BB Biotech AG is using its assets to generate profit.

  • Above 5% is considered healthy but always compare BB Biotech AG to the Biotechnology industry mean.
  • 4.1% Return on Assets means that BB Biotech AG generated CHF0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BB Biotech AG:

  • The MRQ is 4.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is -2.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ4.1%TTM-2.0%+6.2%
TTM-2.0%YOY-3.0%+1.0%
TTM-2.0%5Y-0.5%-1.5%
5Y-0.5%10Y0.4%-0.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1%-13.3%+17.4%
TTM-2.0%-12.7%+10.7%
YOY-3.0%-11.8%+8.8%
5Y-0.5%-14.0%+13.5%
10Y0.4%-15.9%+16.3%
1.1.3. Return on Equity

Shows how efficient BB Biotech AG is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare BB Biotech AG to the Biotechnology industry mean.
  • 4.7% Return on Equity means BB Biotech AG generated CHF0.05 for each CHF1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BB Biotech AG:

  • The MRQ is 4.7%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -2.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ4.7%TTM-2.3%+7.0%
TTM-2.3%YOY-3.4%+1.1%
TTM-2.3%5Y-0.7%-1.6%
5Y-0.7%10Y0.3%-1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.7%-16.9%+21.6%
TTM-2.3%-16.0%+13.7%
YOY-3.4%-15.1%+11.7%
5Y-0.7%-19.7%+19.0%
10Y0.3%-20.5%+20.8%

1.2. Operating Efficiency of BB Biotech AG.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient BB Biotech AG is operating .

  • Measures how much profit BB Biotech AG makes for each CHF1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare BB Biotech AG to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated CHF0.00  for each CHF1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BB Biotech AG:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM179.4%-179.4%
TTM179.4%YOY59.7%+119.7%
TTM179.4%5Y-207.6%+387.0%
5Y-207.6%10Y-122.2%-85.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--290.9%+290.9%
TTM179.4%-224.4%+403.8%
YOY59.7%-288.3%+348.0%
5Y-207.6%-479.5%+271.9%
10Y-122.2%-625.2%+503.0%
1.2.2. Operating Ratio

Measures how efficient BB Biotech AG is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.02 means that the operating costs are CHF0.02 for each CHF1 in net sales.

Let's take a look of the Operating Ratio trends of BB Biotech AG:

  • The MRQ is 0.018. The company is very efficient in keeping operating costs low. +2
  • The TTM is -0.603.
Trends
Current periodCompared to+/- 
MRQ0.018TTM-0.603+0.621
TTM-0.603YOY-0.031-0.572
TTM-0.6035Y2.643-3.246
5Y2.64310Y1.495+1.148
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0183.110-3.092
TTM-0.6033.266-3.869
YOY-0.0313.783-3.814
5Y2.6435.657-3.014
10Y1.4957.783-6.288

1.3. Liquidity of BB Biotech AG.

1.3. Liquidity
1.3.1. Current Ratio

Measures if BB Biotech AG is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.00 means the company has CHF0.00 in assets for each CHF1 in short-term debts.

Let's take a look of the Current Ratio trends of BB Biotech AG:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.005-0.005
TTM0.005YOY2.471-2.465
TTM0.0055Y10.945-10.939
5Y10.94510Y7.809+3.136
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.905-3.905
TTM0.0054.212-4.207
YOY2.4715.337-2.866
5Y10.9456.062+4.883
10Y7.8096.401+1.408
1.3.2. Quick Ratio

Measures if BB Biotech AG is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare BB Biotech AG to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off CHF0.00 for each CHF1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BB Biotech AG:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM6.126-6.126
TTM6.126YOY11.301-5.175
TTM6.1265Y15.272-9.146
5Y15.27210Y7.834+7.438
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.572-3.572
TTM6.1264.001+2.125
YOY11.3015.364+5.937
5Y15.2726.009+9.263
10Y7.8346.287+1.547

1.4. Solvency of BB Biotech AG.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of BB Biotech AG assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare BB Biotech AG to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that BB Biotech AG assets are financed with 11.6% credit (debt) and the remaining percentage (100% - 11.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BB Biotech AG:

  • The MRQ is 0.116. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.119. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.116TTM0.119-0.004
TTM0.119YOY0.113+0.006
TTM0.1195Y0.098+0.021
5Y0.09810Y0.080+0.018
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1160.336-0.220
TTM0.1190.334-0.215
YOY0.1130.271-0.158
5Y0.0980.366-0.268
10Y0.0800.389-0.309
1.4.2. Debt to Equity Ratio

Measures if BB Biotech AG is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare BB Biotech AG to the Biotechnology industry mean.
  • A Debt to Equity ratio of 13.1% means that company has CHF0.13 debt for each CHF1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BB Biotech AG:

  • The MRQ is 0.131. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.136. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.131TTM0.136-0.004
TTM0.136YOY0.128+0.008
TTM0.1365Y0.110+0.026
5Y0.11010Y0.089+0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1310.382-0.251
TTM0.1360.397-0.261
YOY0.1280.341-0.213
5Y0.1100.432-0.322
10Y0.0890.465-0.376

2. Market Valuation of BB Biotech AG

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every CHF1 in earnings BB Biotech AG generates.

  • Above 15 is considered overpriced but always compare BB Biotech AG to the Biotechnology industry mean.
  • A PE ratio of 5.37 means the investor is paying CHF5.37 for every CHF1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BB Biotech AG:

  • The EOD is 5.177. Based on the earnings, the company is cheap. +2
  • The MRQ is 5.372. Based on the earnings, the company is cheap. +2
  • The TTM is -12.430. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD5.177MRQ5.372-0.195
MRQ5.372TTM-12.430+17.802
TTM-12.430YOY-6.105-6.325
TTM-12.4305Y-2.035-10.395
5Y-2.03510Y1.441-3.476
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.177-2.262+7.439
MRQ5.372-2.599+7.971
TTM-12.430-2.674-9.756
YOY-6.105-4.133-1.972
5Y-2.035-6.258+4.223
10Y1.441-6.171+7.612
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BB Biotech AG:

  • The EOD is -608.743. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -631.645. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -122.185. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-608.743MRQ-631.645+22.902
MRQ-631.645TTM-122.185-509.460
TTM-122.185YOY0.754-122.939
TTM-122.1855Y-18.413-103.772
5Y-18.41310Y30.334-48.748
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-608.743-2.913-605.830
MRQ-631.645-3.275-628.370
TTM-122.185-3.508-118.677
YOY0.754-5.620+6.374
5Y-18.413-8.306-10.107
10Y30.334-8.854+39.188
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of BB Biotech AG is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.01 means the investor is paying CHF1.01 for each CHF1 in book value.

Let's take a look of the Price to Book Ratio trends of BB Biotech AG:

  • The EOD is 0.969. Based on the equity, the company is cheap. +2
  • The MRQ is 1.005. Based on the equity, the company is underpriced. +1
  • The TTM is 1.049. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.969MRQ1.005-0.036
MRQ1.005TTM1.049-0.043
TTM1.049YOY1.180-0.131
TTM1.0495Y1.151-0.102
5Y1.15110Y1.707-0.556
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.9691.858-0.889
MRQ1.0052.090-1.085
TTM1.0492.091-1.042
YOY1.1802.866-1.686
5Y1.1513.488-2.337
10Y1.7073.836-2.129
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of BB Biotech AG compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.071-1.629+179%-2.537+222%-0.477+123%0.108+1824%
Book Value Per Share--42.52441.241+3%48.596-12%54.450-22%55.688-24%
Current Ratio---0.005-100%2.471-100%10.945-100%7.809-100%
Debt To Asset Ratio--0.1160.119-3%0.113+2%0.098+18%0.080+45%
Debt To Equity Ratio--0.1310.136-3%0.128+3%0.110+19%0.089+48%
Dividend Per Share---2.121-100%3.349-100%3.041-100%2.203-100%
Eps--1.989-0.940+147%-1.617+181%0.348+471%0.714+179%
Free Cash Flow Per Share---0.0170.994-102%-2.539+14908%0.033-152%0.334-105%
Free Cash Flow To Equity Per Share--0.005-0.009+268%-3.595+68325%-0.734+14039%-0.380+7308%
Gross Profit Margin--0.9860.996-1%1.008-2%1.001-2%1.000-1%
Intrinsic Value_10Y_max--18.653--------
Intrinsic Value_10Y_min---173.528--------
Intrinsic Value_1Y_max--1.414--------
Intrinsic Value_1Y_min---5.180--------
Intrinsic Value_3Y_max--4.596--------
Intrinsic Value_3Y_min---26.230--------
Intrinsic Value_5Y_max--8.195--------
Intrinsic Value_5Y_min---58.809--------
Market Cap2259655200.000-4%2344666500.0002386272300.913-2%3152569582.450-26%3491999778.173-33%5372649866.994-56%
Net Profit Margin--0.9821.515-35%1.013-3%-92.279+9502%-46.830+4871%
Operating Margin---1.794-100%0.597-100%-2.0760%-1.2220%
Operating Ratio--0.018-0.603+3421%-0.031+270%2.643-99%1.495-99%
Pb Ratio0.969-4%1.0051.049-4%1.180-15%1.151-13%1.707-41%
Pe Ratio5.177-4%5.372-12.430+331%-6.105+214%-2.035+138%1.441+273%
Price Per Share41.200-4%42.75043.275-1%57.300-25%62.930-32%96.408-56%
Price To Free Cash Flow Ratio-608.743+4%-631.645-122.185-81%0.754-83866%-18.413-97%30.334-2182%
Price To Total Gains Ratio19.889-4%20.63712.011+72%-29.563+243%1.687+1123%148.010-86%
Quick Ratio---6.126-100%11.301-100%15.272-100%7.834-100%
Return On Assets--0.041-0.020+149%-0.030+172%-0.005+113%0.004+874%
Return On Equity--0.047-0.023+149%-0.034+173%-0.007+114%0.003+1531%
Total Gains Per Share--2.0710.492+321%0.812+155%2.564-19%2.311-10%
Usd Book Value--2557549736.4002494953889.350+3%2931323104.900-13%3312816208.420-23%3392618959.313-25%
Usd Book Value Change Per Share--2.272-1.786+179%-2.782+222%-0.523+123%0.118+1824%
Usd Book Value Per Share--46.63145.225+3%53.291-12%59.710-22%61.068-24%
Usd Dividend Per Share---2.326-100%3.672-100%3.335-100%2.416-100%
Usd Eps--2.182-1.031+147%-1.773+181%0.382+471%0.783+179%
Usd Free Cash Flow---1017644.80059840365.400-102%-153584587.150+14992%2233664.540-146%20444813.574-105%
Usd Free Cash Flow Per Share---0.0191.090-102%-2.785+14908%0.036-152%0.366-105%
Usd Free Cash Flow To Equity Per Share--0.006-0.010+268%-3.942+68325%-0.805+14039%-0.417+7308%
Usd Market Cap2477937892.320-4%2571161283.9002616786205.181-2%3457107804.115-26%3829326956.744-33%5891647844.145-56%
Usd Price Per Share45.180-4%46.88047.455-1%62.835-25%69.009-32%105.721-56%
Usd Profit--119656605.600-56641309.050+147%-98094159.800+182%-2418852.865+102%31725101.946+277%
Usd Revenue--121909022.000-51074967.450+142%-91334717.400+175%20999506.190+481%81763452.010+49%
Usd Total Gains Per Share--2.2720.540+321%0.890+155%2.812-19%2.534-10%
 EOD+3 -5MRQTTM+21 -15YOY+19 -175Y+16 -1910Y+15 -20

3.2. Fundamental Score

Let's check the fundamental score of BB Biotech AG based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-155.177
Price to Book Ratio (EOD)Between0-10.969
Net Profit Margin (MRQ)Greater than00.982
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than10.000
Debt to Asset Ratio (MRQ)Less than10.116
Debt to Equity Ratio (MRQ)Less than10.131
Return on Equity (MRQ)Greater than0.150.047
Return on Assets (MRQ)Greater than0.050.041
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of BB Biotech AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose41.000
Total0/1 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Income before Tax  -35,161-218,678-253,839240,375-13,464-34,911-48,375157,525109,150
Net Income  -35,164-218,691-253,855240,377-13,478-34,912-48,390157,506109,116
Gross Profit  -33,598-218,496-252,094247,419-4,675-36,029-40,704151,874111,170
EBITDA  -35,161-217,570-252,731239,267-13,464-34,911-48,375157,525109,150
Operating Income  -35,161-217,570-252,731239,267-13,464-34,911-48,375157,525109,150
Total Revenue -33,598-218,496-252,094247,419-4,675-36,029-40,704151,874111,170
Net Income from Continuing Operations  -35,164-218,691-253,855240,377-13,478-34,912-48,390157,506109,116



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in CHF. All numbers in thousands.

Summary
Total Assets2,637,154
Total Liabilities304,900
Total Stockholder Equity2,323,217
 As reported
Total Liabilities 304,900
Total Stockholder Equity+ 2,323,217
Total Assets = 2,637,154

Assets

Total Assets2,637,154
Total Current Assets2,330
Long-term Assets2,634,714
Total Current Assets
Cash And Cash Equivalents 501
Net Receivables 1,829
Total Current Assets  (as reported)2,330
Total Current Assets  (calculated)2,330
+/-0
Long-term Assets
Long Term Investments 2,634,714
Other Assets 110
Long-term Assets  (as reported)2,634,714
Long-term Assets  (calculated)2,634,824
+/- 110

Liabilities & Shareholders' Equity

Total Current Liabilities0
Long-term Liabilities304,900
Total Stockholder Equity2,323,217
Total Current Liabilities
Total Current Liabilities  (as reported)0
Total Current Liabilities  (calculated)0
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)304,900
Long-term Liabilities  (calculated)0
+/- 304,900
Total Stockholder Equity
Common Stock11,080
Retained Earnings 2,348,645
Other Stockholders Equity -36,508
Total Stockholder Equity (as reported)2,323,217
Total Stockholder Equity (calculated)2,323,217
+/-0
Other
Capital Stock11,080
Cash and Short Term Investments 501
Common Stock Shares Outstanding 54,846
Liabilities and Stockholders Equity 2,637,154
Net Debt 304,399
Net Invested Capital 2,628,117
Short Long Term Debt Total 304,900



Balance Sheet

Currency in CHF. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-31
> Total Assets 
0
0
0
1,520,847
1,539,076
1,359,272
1,327,890
1,376,979
1,356,826
1,273,385
1,052,130
1,151,606
1,233,745
1,404,183
1,544,503
1,373,948
1,679,900
1,783,833
2,183,617
2,210,872
2,283,398
2,477,499
2,931,542
3,532,793
3,747,518
4,069,221
3,552,231
4,143,667
2,952,432
2,977,868
3,256,359
3,226,237
3,531,518
3,359,172
3,637,799
3,689,111
3,651,231
3,859,684
3,086,844
3,987,462
3,644,645
3,234,388
0
0
0
3,480,538
3,963,135
4,282,917
4,357,070
4,094,990
3,644,082
3,120,514
2,854,302
3,028,179
3,053,389
2,595,333
2,578,461
2,520,741
2,637,154
2,637,1542,520,7412,578,4612,595,3333,053,3893,028,1792,854,3023,120,5143,644,0824,094,9904,357,0704,282,9173,963,1353,480,5380003,234,3883,644,6453,987,4623,086,8443,859,6843,651,2313,689,1113,637,7993,359,1723,531,5183,226,2373,256,3592,977,8682,952,4324,143,6673,552,2314,069,2213,747,5183,532,7932,931,5422,477,4992,283,3982,210,8722,183,6171,783,8331,679,9001,373,9481,544,5031,404,1831,233,7451,151,6061,052,1301,273,3851,356,8261,376,9791,327,8901,359,2721,539,0761,520,847000
   > Total Current Assets 
0
0
0
0
0
0
0
0
1,356,095
1,273,385
0
0
0
1,376,100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,637,799
3,689,111
3,651,231
3,859,684
3,086,844
3,987,462
3,644,645
3,554,567
3,554,567
2,787,821
3,830,779
3,480,538
3,963,135
4,282,917
4,357,070
4,094,990
3,644,082
1,635
1,724
3,028,179
1,948
759
5,502
322
2,330
2,3303225,5027591,9483,028,1791,7241,6353,644,0824,094,9904,357,0704,282,9173,963,1353,480,5383,830,7792,787,8213,554,5673,554,5673,644,6453,987,4623,086,8443,859,6843,651,2313,689,1113,637,799000000000000000000001,376,1000001,273,3851,356,09500000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
12,146
17,383
0
0
0
5,932
0
18,857
20,886
12,615
22,380
43,699
15,089
31,028
25,889
8,968
11,224
132,915
3,761
21,059
16,219
13,280
14,491
10,229
6,202
23,007
10,730
9,317
14,796
10,172
22,072
8,407
8,796
9,423
0
0
0
14,883
6,816
3,914
3,174
1,775
2,835
1,635
1,724
0
1,948
759
900
322
501
5013229007591,94801,7241,6352,8351,7753,1743,9146,81614,8830009,4238,7968,40722,07210,17214,7969,31710,73023,0076,20210,22914,49113,28016,21921,0593,761132,91511,2248,96825,88931,02815,08943,69922,38012,61520,88618,85705,93200017,38312,14600000000
       Short-term Investments 
0
0
0
0
0
0
0
0
1,332,318
1,245,064
0
0
0
1,367,647
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,465,526
3,954,659
4,278,768
4,349,265
4,093,103
3,641,112
3,118,719
2,852,415
3,025,046
3,035,170
2,594,360
2,572,727
2,520,315
0
02,520,3152,572,7272,594,3603,035,1703,025,0462,852,4153,118,7193,641,1124,093,1034,349,2654,278,7683,954,6593,465,52600000000000000000000000000000001,367,6470001,245,0641,332,31800000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,421
4,475
22,449
0
9,920
13,567
24,787
0
7,841
8,707
0
3,978
5,747
19,435
0
10,151
1,076
3,526
0
0
28,822
4,878
334
20,109
1,253
0
0
0
5,829
0
1,521
0
4,457
0
0
0
0
0
0
0
4,602
0
1,829
1,82904,60200000004,45701,52105,8290001,25320,1093344,87828,822003,5261,07610,151019,4355,7473,97808,7077,841024,78713,5679,920022,4494,47513,4210000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
11,631
10,938
0
0
0
2,521
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,140
3,782
1,145
496
466
182
265
4,875
4,875
5,413
5,127
4,028
2,294
2,532
2,426
2,380
2,357
160
163
108
3,051,441
2,594,574
2,577,561
2,520,419
0
02,520,4192,577,5612,594,5743,051,4411081631602,3572,3802,4262,5322,2944,0285,1275,4134,8754,8752651824664961,1453,7823,140000000000000000000002,52100010,93811,63100000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
731
0
0
0
0
28,083
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,118,719
2,152,415
0
3,051,349
2,594,360
2,572,727
2,520,315
2,634,714
2,634,7142,520,3152,572,7272,594,3603,051,34902,152,4153,118,719000000000000000000000000000000000000028,083000073100000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,118,719
2,152,415
0
3,051,349
2,594,360
2,572,727
2,520,315
2,634,714
2,634,7142,520,3152,572,7272,594,3603,051,34902,152,4153,118,719000000000000000000000000000000000000000000000000000
       Other Assets 
0
0
0
1,520,847
1,539,076
1,359,272
1,327,890
1,376,979
0
0
1,052,130
1,151,606
1,233,745
0
1,544,503
1,373,948
1,679,900
1,783,833
2,183,617
2,210,872
2,283,398
2,477,499
2,931,542
3,532,793
3,747,518
4,069,221
3,552,231
4,143,667
2,952,432
2,977,868
3,256,359
3,226,237
3,531,518
3,359,172
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
160
700,163
0
92
214
232
104
110
110104232214920700,163160000000000000000003,359,1723,531,5183,226,2373,256,3592,977,8682,952,4324,143,6673,552,2314,069,2213,747,5183,532,7932,931,5422,477,4992,283,3982,210,8722,183,6171,783,8331,679,9001,373,9481,544,50301,233,7451,151,6061,052,130001,376,9791,327,8901,359,2721,539,0761,520,847000
> Total Liabilities 
0
0
0
4,626
67,623
189,194
143,009
142,149
167,713
184,677
125,751
149,888
117,377
163,788
164,082
139,943
140,807
103,598
149,389
92,000
182,433
186,282
159,423
40,268
42,207
33,152
94,137
165,509
354,484
356,541
243,220
223,218
313,666
30,121
99,124
305,029
365,731
332,319
202,332
382,139
375,127
346,636
0
0
0
249,436
75,588
364,464
310,070
261,755
360,589
359,636
334,462
306,880
363,000
315,500
308,500
302,100
304,900
304,900302,100308,500315,500363,000306,880334,462359,636360,589261,755310,070364,46475,588249,436000346,636375,127382,139202,332332,319365,731305,02999,12430,121313,666223,218243,220356,541354,484165,50994,13733,15242,20740,268159,423186,282182,43392,000149,389103,598140,807139,943164,082163,788117,377149,888125,751184,677167,713142,149143,009189,19467,6234,626000
   > Total Current Liabilities 
0
0
0
0
0
0
0
0
167,713
184,677
0
0
0
161,145
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
99,124
305,029
365,731
332,319
202,332
382,139
375,127
161,594
161,594
341,162
204,460
249,436
75,588
364,464
310,070
261,755
360,589
359,636
334,462
306,880
367,254
319,364
315,970
306,640
0
0306,640315,970319,364367,254306,880334,462359,636360,589261,755310,070364,46475,588249,436204,460341,162161,594161,594375,127382,139202,332332,319365,731305,02999,12400000000000000000000161,145000184,677167,71300000000
       Short-term Debt 
0
0
0
0
0
0
0
0
145,000
175,092
0
0
0
150,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
245,000
63,000
350,000
300,000
248,000
355,000
355,000
326,000
303,000
363,000
315,500
308,500
302,100
0
0302,100308,500315,500363,000303,000326,000355,000355,000248,000300,000350,00063,000245,0000000000000000000000000000000000150,000000175,092145,00000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
8,536
0
0
0
5,129
0
151
0
0
0
134
0
0
0
2,683
0
0
0
3,354
0
0
0
2,884
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000002,8840003,3540002,68300013400015105,1290008,536000000000
       Other Current Liabilities 
0
0
0
0
0
0
0
0
22,713
1,049
0
0
0
6,016
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
724
4,293
4,014
4,302
969
4,773
4,653
1,690
1,690
4,162
4,658
4,436
2,297
6,009
5,915
5,976
1,623
4,636
3,822
3,880
367,254
319,364
315,970
306,640
0
0306,640315,970319,364367,2543,8803,8224,6361,6235,9765,9156,0092,2974,4364,6584,1621,6901,6904,6534,7739694,3024,0144,293724000000000000000000006,0160001,04922,71300000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
2,643
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
225,000
205,000
310,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
359,636
334,462
0
363,000
315,500
308,500
302,100
304,900
304,900302,100308,500315,500363,0000334,462359,636000000000000000000310,000205,000225,00000000000000000002,6430000000000000
> Total Stockholder Equity
0
0
0
1,516,221
1,471,453
1,170,078
1,184,881
1,234,830
1,189,113
1,088,708
926,379
1,001,718
1,116,368
1,240,395
1,380,421
1,234,005
1,539,093
1,680,235
2,034,228
2,118,872
2,100,965
2,291,217
2,772,119
3,492,525
3,705,311
4,036,069
3,458,094
3,978,158
2,597,948
2,621,327
3,013,139
3,003,019
3,217,852
3,329,051
3,538,675
3,384,082
3,285,500
3,527,365
2,884,512
3,605,323
3,269,518
2,887,752
0
0
0
3,231,102
3,887,547
3,918,453
4,047,000
3,833,235
3,283,493
2,760,878
2,519,840
2,721,299
2,686,135
2,275,969
2,262,491
2,214,101
2,323,217
2,323,2172,214,1012,262,4912,275,9692,686,1352,721,2992,519,8402,760,8783,283,4933,833,2354,047,0003,918,4533,887,5473,231,1020002,887,7523,269,5183,605,3232,884,5123,527,3653,285,5003,384,0823,538,6753,329,0513,217,8523,003,0193,013,1392,621,3272,597,9483,978,1583,458,0944,036,0693,705,3113,492,5252,772,1192,291,2172,100,9652,118,8722,034,2281,680,2351,539,0931,234,0051,380,4211,240,3951,116,3681,001,718926,3791,088,7081,189,1131,234,8301,184,8811,170,0781,471,4531,516,221000
   Common Stock
0
0
0
18,225
18,225
18,225
18,225
18,225
18,225
18,225
16,403
16,403
14,762
13,000
13,000
13,000
13,000
11,850
11,850
11,850
11,850
11,850
11,850
11,850
11,850
11,850
11,850
11,850
11,850
11,850
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,080
11,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,08011,85011,85011,85011,85011,85011,85011,85011,85011,85011,85011,85011,85011,85013,00013,00013,00013,00014,76216,40316,40318,22518,22518,22518,22518,22518,22518,225000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000000000000000000000000000000000
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000-9,205-5,36800-8,2410000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
313,551
286,757
273,635
254,895
237,931
199,854
183,754
152,233
119,032
41,907
7,363
-1,247
-13,112
-66,626
-58,425
-43,195
-58,929
-142,486
-147,659
-149,576
-77,670
-114,571
-121,319
-126,995
-119,332
-133,601
-145,816
-13,092
-859
-9,086
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-19,716
-27,689
0
-36,508
-36,508
-36,508
-36,508
-36,508
-36,508-36,508-36,508-36,508-36,5080-27,689-19,716000000000000000000-9,086-859-13,092-145,816-133,601-119,332-126,995-121,319-114,571-77,670-149,576-147,659-142,486-58,929-43,195-58,425-66,626-13,112-1,2477,36341,907119,032152,233183,754199,854237,931254,895273,635286,757313,551000



Balance Sheet

Currency in CHF. All numbers in thousands.




Cash Flow

Currency in CHF. All numbers in thousands.




Income Statement

Currency in CHF. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue-199,567
Cost of Revenue-0
Gross Profit-199,567-199,567
 
Operating Income (+$)
Gross Profit-199,567
Operating Expense-6,960
Operating Income-206,528-206,527
 
Operating Expense (+$)
Research Development0
Selling General Administrative4,347
Selling And Marketing Expenses1,567
Operating Expense6,9605,914
 
Net Interest Income (+$)
Interest Income35
Interest Expense-5,802
Other Finance Cost-0
Net Interest Income-5,767
 
Pretax Income (+$)
Operating Income-206,528
Net Interest Income-5,767
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-206,528-206,528
EBIT - interestExpense = -5,802
-206,528
-200,805
Interest Expense5,802
Earnings Before Interest and Taxes (EBIT)0-200,726
Earnings Before Interest and Taxes (EBITDA)-206,528
 
After tax Income (+$)
Income Before Tax-206,528
Tax Provision-79
Net Income From Continuing Ops-206,607-206,607
Net Income-206,607
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses6,960
Total Other Income/Expenses Net05,767
 

Technical Analysis of BB Biotech AG
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of BB Biotech AG. The general trend of BB Biotech AG is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine BB Biotech AG's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BB Biotech AG.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 47.40 < 47.69 < 48.32.

The bearish price targets are: 40.50 > 37.92 > 37.87.

Tweet this
BB Biotech AG Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BB Biotech AG. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BB Biotech AG Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BB Biotech AG.

BB Biotech AG Daily Moving Average Convergence/Divergence (MACD) ChartBB Biotech AG Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BB Biotech AG. The current adx is .

BB Biotech AG Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BB Biotech AG.

BB Biotech AG Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BB Biotech AG.

BB Biotech AG Daily Relative Strength Index (RSI) ChartBB Biotech AG Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BB Biotech AG.

BB Biotech AG Daily Stochastic Oscillator ChartBB Biotech AG Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BB Biotech AG.

BB Biotech AG Daily Commodity Channel Index (CCI) ChartBB Biotech AG Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BB Biotech AG.

BB Biotech AG Daily Chande Momentum Oscillator (CMO) ChartBB Biotech AG Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BB Biotech AG.

BB Biotech AG Daily Williams %R ChartBB Biotech AG Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BB Biotech AG.

BB Biotech AG Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BB Biotech AG.

BB Biotech AG Daily Average True Range (ATR) ChartBB Biotech AG Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BB Biotech AG.

BB Biotech AG Daily On-Balance Volume (OBV) ChartBB Biotech AG Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BB Biotech AG.

BB Biotech AG Daily Money Flow Index (MFI) ChartBB Biotech AG Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BB Biotech AG.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

BB Biotech AG Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BB Biotech AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose41.000
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of BB Biotech AG with someone you think should read this too:
  • Are you bullish or bearish on BB Biotech AG? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about BB Biotech AG? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BB Biotech AG

I send you an email if I find something interesting about BB Biotech AG.


Comments

How you think about this?

Leave a comment

Stay informed about BB Biotech AG.

Receive notifications about BB Biotech AG in your mailbox!